Fate Therapeutics (NASDAQ:FATE) Navigates Q1 Earnings with EPS Beat and Clinical Trial Momentum

Font: Financial Modeling Prep  • May 13, 2026

• Fate Therapeutics reported an earnings per share of -$0.26, surpassing the consensus estimate of -$0.30.
• The biopharmaceutical company's revenue for the quarter was $1.3 million, falling short of the anticipated $1.49 million.
• Fate Therapeutics confirmed its FT819 Phase 2 clinical trial is on schedule and extended its operating runway into 2028 after a 20% reduction in operating expenses.

Fate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharmaceutical company. It focuses on developing cellular immunotherapies to treat cancer and immune disorders. A key program for the company is its FT819 treatment, which is being studied for its potential to help patients with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease.

On May 13, 2026, Fate Therapeutics reported its first-quarter financial results. The company announced an earnings per share of -$0.26. This figure was better than the consensus estimate of -$0.30. As highlighted by Zacks, this also marks an improvement from the loss of $0.32 per share that was reported in the same quarter one year ago.

However, the company's revenue for the quarter was $1.3 million, which did not meet the anticipated $1.49 million. This revenue figure missed the consensus estimate by over 25%. It also represents a decline from the $1.63 million in revenue that was recorded in the prior-year period, showing a drop in sales.

The company's current unprofitability is reflected in its negative Price-to-Earnings (P/E) ratio of -1.82. A negative P/E ratio indicates that a company has had negative earnings over the last twelve months. Despite this, Fate Therapeutics has a strong Current Ratio of 5.85, which suggests it has a solid ability to meet its short-term financial obligations.

In a business update highlighted by GlobeNewswire, Fate Therapeutics confirmed its Phase 2 clinical trial for FT819 is on schedule to start in the second half of 2026. The company also extended its operating runway into 2028. This was achieved after a 20% reduction in operating expenses during the first quarter of 2026.